Peripheral artery disease
- PMID: 40968271
- DOI: 10.1038/s41572-025-00651-0
Peripheral artery disease
Abstract
Peripheral artery disease (PAD) is characterized by blockage of the arteries that supply the lower extremities, often occurring as a result of atherosclerosis and thrombosis. PAD affects approximately 230 million people worldwide, with a growing prevalence owing to population ageing and concomitant cardiovascular risk factors, including smoking, diabetes mellitus, hypertension and dyslipidaemia. Patients with PAD have an increased risk of major cardiovascular and limb events, and substantially poorer walking performance compared with those without PAD. The screening and identification of PAD involves clinical and imaging assessments of disease extent and severity and stratification of individual risk to ensure appropriate management. Patients with PAD should be treated with guideline-directed medical therapy (GDMT), including antithrombotic, lipid-lowering, glucose-lowering and anti-hypertensive therapies, and exercise therapies that aim to improve function as well as cardiovascular and limb outcomes. For patients with compromised limb viability, such as acute and chronic limb-threatening ischaemia, or severe functional impairment that does not improve with exercise training, lower extremity revascularization is recommended. Given the complexity of PAD management, a multidisciplinary vascular team is required to achieve the best individualized treatment. Further research efforts should focus on reducing ischaemic events and health disparities and on optimizing the implementation of GDMT and exercise therapy, as well as improving the quality of life in patients with PAD.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: V.A. has received, over the past 3 years, honoraria from: Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim and Novo-Nordisk. M.E.C. and M.P.B. receive salary support from CPC, a non-profit academic research organization affiliated with the University of Colorado that receives or has received research grant and/or consulting funding between August 2021 and the present from: Abbott Laboratories, Agios Pharmaceuticals, Inc., Alexion Pharma, Alnylam Pharmaceuticals, Inc., Amgen, Inc., Angionetics, Inc., Anthos Therapeutics, Array BioPharma, Inc., AstraZeneca and affiliates, Atentiv LLC, Audentes Therapeutics, Inc., Bayer and affiliates, Bristol-Meyers Squibb, Cambrian Biopharma, Inc., Cardiol Therapeutics, Inc., CellResearch Corp., Cleerly, Inc., Cook Regentec LLC, CSL Behring LLC, Eidos Therapeutics, Inc., EP Trading Co. Ltd, Epizon Pharma, Inc., Esperion Therapeutics, Inc., Everly Well, Inc., Exicon Consulting Pvt. Ltd, Faraday Pharmaceuticals, Inc., Foresee Pharmaceuticals Co. Ltd, Fortress Biotech, Inc., HDL Therapeutics, Inc., HeartFlow, Inc., Hummingbird Bioscience, Insmed, Inc., Ionis Pharmaceuticals, Janssen and affiliates, Kowa Research Institute, Inc., Lexicon Pharmaceuticals, Inc., MedImmune Ltd, Merck & affiliates, Nectero Medical, Inc., Novartis Pharmaceuticals Corp., Novo-Nordisk, Inc., Osiris Therapeutics, Inc., Pfizer, Inc., PhaseBio Pharmaceuticals, Inc., Prairie Education and Research Cooperative, Prothena Biosciences Ltd, Regeneron Pharmaceuticals, Inc., Regio Biosciences, Inc., Sanofi–Aventis Group, Silence Therapeutics PLC, Smith & Nephew plc, Stealth BioTherapeutics, Inc., Tourmaline Bio, Inc., VarmX, and Virta Health Corporation. M.M.M. receives research support from Mars and ACI Medical. The other authors declare no competing interests.
References
-
- Gornik, H. L. et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation 149, e1313–e1410 (2024). PAD guidelines from the USA. - PubMed - DOI